Non-nucleoside Reverse Transcriptase Inhibitor
Semantic Scholar uses AI to extract papers important to this topic.
Rilpivirine is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) that is approved for HIV-1 treatment-naive adult… Expand BACKGROUND
The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TMC278; Tibotec Pharmaceuticals, County Cork… Expand Programs that monitor local, national, and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines and… Expand OBJECTIVES
The aim of this study was to investigate the frequency of CYP2B6 polymorphisms (according to ethnicity) and the… Expand Objectives:Monitoring regional levels of transmitted HIV-1 resistance informs treatment guidelines and provides feedback on the… Expand Objective:To compare the prevalence of resistance by adherence level in patients treated with non-nucleoside reverse… Expand AIMS
To characterize the demographic and pharmacogenetic factors that influence interpatient variability in the plasma… Expand Anti-AIDS drug candidate and non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125-R165335 (etravirine) caused an initial… Expand Objective: We have shown that HIV-1 clade C variants contain a valine codon 106 polymorphism (GTG) that facilitates a V106M… Expand OBJECTIVE
New information warrants updated recommendations for the 4 central issues in antiretroviral therapy: when to start… Expand